Evidence map›Paper›PMID 33715941›Full record

ReviewTrends in parasitology2021

Genomic and Genetic Approaches to Studying Antimalarial Drug Resistance and Plasmodium Biology.

John Okombo, Mariko Kanai, Ioanna Deni, David A Fidock

Open access · greenAbstract readReview
In one paragraph

Review in Trends in parasitology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Novel systems to study vector-pathogen interactions in malaria.Frontiers in cellular and infection microbiology · 2023
    Review
  10. Current and emerging target identification methods for novel antimalarials.International journal for parasitology. Drugs and drug resistance · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Novel Compounds for Treating Malaria.ACS medicinal chemistry letters · 2021
    Article
  15. Novel Hexahydropyrimidine Compounds for Treating Malaria.ACS medicinal chemistry letters · 2021
    Article
  16. Methods Used to Investigate theFrontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

John OkomboDepartment of Microbiology & Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Mariko KanaiDepartment of Microbiology & Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Ioanna DeniDepartment of Microbiology & Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
David A FidockDepartment of Microbiology & Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. Electronic address: df2660@cumc.columbia.edu.
Columbia University Irving Medical Center · US

Funding

Leveraging PfCRT Structure to Discern Function and Predict Emergence of Drug-Resistant MalariaR01AI147628 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock, Filippo Mancia · 2019 to 2026
$5.1M
Defining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4M
Elucidating the molecular basis of piperaquine resistance in Plasmodium falciparumR01AI124678 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2016 to 2026
$4.3M
Parasite-specific proteasome inhibitors to combat multi-drug resistant malariaR33AI127581 · NIAID · STANFORD UNIVERSITY · PI BOGYO, MATTHEW · 2019 to 2021
$1.4M
NIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI124678NIAID NIH HHS R01 AI147628NIAID NIH HHS R33 AI127581
6 · The paper itself

Abstract

Recent progress in genomics and molecular genetics has empowered novel approaches to study gene functions in disease-causing pathogens. In the human malaria parasite Plasmodium falciparum, the application of genome-based analyses, site-directed genome editing, and genetic systems that allow for temporal and quantitative regulation of gene and protein expression have been invaluable in defining the genetic basis of antimalarial resistance and elucidating candidate targets to accelerate drug discovery efforts. Using examples from recent studies, we review applications of some of these approaches in advancing our understanding of Plasmodium biology and illustrate their contributions and limitations in characterizing parasite genomic loci associated with antimalarial drug responses.

Indexed as

GenomicsMolecular BiologyAntimalarialsDrug ResistanceGenome, ProtozoanHumansMalaria, FalciparumPlasmodium falciparumAntimalarialsdrug resistancegene editinggenetic crossesgenomicsinducible expressionPlasmodium falciparum malaria

Identifiers

PMID33715941
PMCPMC8162148
OpenAlexW3134231146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.